Lisinopril attenuates renal oxidative injury in L-NAME-induced hypertensive rats. 2011

Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
Department of Pediatric Nephrology, School of Medicine, Bezmialem Vakif University, İstanbul, Turkey. oktemfaruk@hotmail.com

Hypertension and related oxidative stress are involved in the pathogenesis of any renal diseases. Angiotensin-converting enzyme inhibitors have multi-directional renoprotective effects. In this study, we aimed to investigate whether lisinopril treatment has any biochemical alterations on renal tissue in L-NAME (Nε-nitro-L-arginine methyl ester) induced hypertension model. Twenty-eight Sprague-Dawley rats were included in this study and divided into four equal groups (n = 7): control group, L-NAME treated group (75 mg/kg/day), L-NAME plus lisinopril treated group and only lisinopril treated group (10 mg/kg/day). L-NAME and lisinopril were continued for 6 weeks. Systolic blood pressures were measured by using tail cuff method. In biochemical analysis, malondialdehyde (MDA, an index of lipid peroxidation) levels, the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in renal tissues were used as markers of oxidative stress-induced renal impairment. Microalbumin and N-acetyl-β-D-glucosaminidase (NAG) in urine were determined as markers of renal tubular damage related to hypertension. Chronic L-NAME administration resulted in a significant depletion of serum nitric oxide (NO). When compared with control group, serum creatinine, microalbumin, urine NAG, renal tissue MDA level, and CAT activities were significantly high, while renal tissue SOD and GSH-Px activities low in L-NAME group. In the L-NAME plus lisinopril treated group, serum creatinine, microalbumin and urine NAG, renal MDA level and CAT activity decreased, whereas SOD, GSH-Px activities in renal tissue and serum NO levels were increased. Thus, lisinopril treatment reversed these effects. There were not any significant difference between L-NAME plus lisinopril treated group and control group concerning serum creatinine, renal tissue MDA level and SOD, GSH-Px, CAT activities. These results suggest that lisinopril could diminish biochemical alterations in L: -NAME induced hypertensive renal damage that occurs by oxidative stress.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D002374 Catalase An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA. Catalase A,Catalase T,Manganese Catalase,Mn Catalase
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013482 Superoxide Dismutase An oxidoreductase that catalyzes the reaction between SUPEROXIDES and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. Hemocuprein,Ag-Zn Superoxide Dismutase,Cobalt Superoxide Dismutase,Cu-Superoxide Dismutase,Erythrocuprein,Fe-Superoxide Dismutase,Fe-Zn Superoxide Dismutase,Iron Superoxide Dismutase,Manganese Superoxide Dismutase,Mn-SOD,Mn-Superoxide Dismutase,Ag Zn Superoxide Dismutase,Cu Superoxide Dismutase,Dismutase, Ag-Zn Superoxide,Dismutase, Cobalt Superoxide,Dismutase, Cu-Superoxide,Dismutase, Fe-Superoxide,Dismutase, Fe-Zn Superoxide,Dismutase, Iron Superoxide,Dismutase, Manganese Superoxide,Dismutase, Mn-Superoxide,Dismutase, Superoxide,Fe Superoxide Dismutase,Fe Zn Superoxide Dismutase,Mn SOD,Mn Superoxide Dismutase,Superoxide Dismutase, Ag-Zn,Superoxide Dismutase, Cobalt,Superoxide Dismutase, Fe-Zn,Superoxide Dismutase, Iron,Superoxide Dismutase, Manganese
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017706 Lisinopril One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. Lisinopril Maleate (1:1),Lisinopril Sulfate (1:2),Lysinopril,MK-521,Prinivil,Zestril

Related Publications

Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
February 2010, Nitric oxide : biology and chemistry,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
October 2015, European journal of pharmacology,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
February 2019, Drug research,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
July 2017, Nitric oxide : biology and chemistry,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
December 2011, European journal of pharmacology,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
March 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
April 2011, American journal of physiology. Renal physiology,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
April 2007, Toxicology,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
August 2007, The Journal of nutritional biochemistry,
Faruk Oktem, and Aynur Kirbas, and Abdullah Armagan, and Ayca Esra Kuybulu, and H Ramazan Yilmaz, and Fehmi Ozguner, and Efkan Uz
December 2004, Fundamental & clinical pharmacology,
Copied contents to your clipboard!